IP Library Granted Patent US 8,778,891
Granted Patent B2
US 8,778,891 · App. 13/884,412 · Granted Jul 15, 2014

Dermatopontin-activating peptides and cosmetic compositions including same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,778,891
App. No.
13/884,412
Granted
Jul 15, 2014
Kind
B2
Abstract

Peptides activating dermatopontin in the skin and cosmetic compositions including such peptide, in a physiologically suitable medium, are described. Methods of treating the cutaneous signs of aging and photoaging, and in particular wrinkles, sagging, and loss of volume and elasticity of the skin are also described.

Claims (132)

1. A peptide of general formula (I):

R 1 -(AA) n -X 1 -Arg-X 2 -Trp-X 3 -X 4 -X 5 -X 6 (R 3 )-(AA) p -R 2

wherein,

X 1 is aspartic acid or absent,

X 2 is glutamine or glutamic acid,

X 3 is asparagine or lysine or glutamine or absent,

X 4 is phenylalanine or tyrosine or absent,

X 5 is tyrosine or alanine or absent,

X 6 is cysteine or absent,

AA is any amino acid and n and p are integers between 0 and 2,

R 1 is the primary amine function of the N-terminal amino acid, free or substituted by a group of the acyl type (R—CO—) wherein the radical R is either a saturated or unsaturated C 1 to C 30 alkyl chain of the acetyl type, or an aromatic group of the benzoyl, tosyl, or benzyloxycarbonyl type,

R 2 is the hydroxyl group of the carboxyl function of the C-terminal amino acid, substituted by a group chosen from a C 1 to C 10 alkyl chain, or an NH 2 , NHY or NYY group with Y representing a C 1 to C 4 alkyl chain or one of the salts thereof,

R 3 is the thiol function of cysteine in the X 6 position, wherein the thiol function is free or substituted by a methyl group or an acetyl group, or the thiol function is covalently bound by a disulfide bond to another cysteine;

with the proviso that when X 1 is absent, n is 0.

2. The peptide of claim 1 , wherein said peptide of general formula (I) is

(SEQ ID NO: 1)

Asp-Arg-Gln-Trp-NH 2 ,

(SEQ ID NO: 2)

Asp-Arg-Glu-Trp-NH 2 ,

(SEQ ID NO: 3)

Asp-Arg-Gln-Trp-Asn-Tyr-NH 2 ,

(SEQ ID NO: 4)

Arg-Glu-Trp-Gln-Phe-Tyr-Cys-NH 2 ,

(SEQ ID NO: 5)

Arg-Glu-Trp-Gln-Phe-Tyr-Cys(Cys)-(NH 2 ),

(SEQ ID NO: 6)

Asp-Arg-Glu-Trp-Gln-Phe-NH 2 ,

(SEQ ID NO: 7)

Asp-Arg-Gln-Trp-Asn-Tyr-Ala-Cys-NH 2 ,

(SEQ ID NO: 8)

Asp-Arg-Gln-Trp-Asn-Tyr-Ala-Cys(Cys)-(NH 2 ),

(SEQ ID NO: 9)

Asp-Arg-Glu-Trp-Gln-Phe-Tyr-Cys-NH 2 ,

(SEQ ID NO: 10)

Asp-Arg-Glu-Trp-Gln-Phe-Tyr-Cys(Cys)-(NH 2 ),

(SEQ ID NO: 11)

Asp-Arg-Gln-Trp-Lys-Phe-NH 2 ,

(SEQ ID NO: 12)

Arg-Glu-Trp-Gln-Phe-Tyr-NH 2 .

3. The peptide of claim 1 , wherein said peptide of general formula (I) is solubilized in one or more physiologically acceptable solvents selected from the group consisting of water, glycerol, ethanol, propanediol, butylene glycol, dipropylene glycol, the ethoxylated or propoxylated diglycols, the cyclic polyols, and mixtures of these solvents.

4. A cosmetic composition comprising:

a peptide of general formula (I):

R 1 -(AA) n -X 1 -Arg-X 2 -Trp-X 3 -X 4 -X 5 -X 6 (R 3 )-(AA) p -R 2

wherein,

X 1 is aspartic acid or absent,

X 2 is glutamine or glutamic acid,

X 3 is asparagine or lysine or glutamine or absent,

X 4 is phenylalanine or tyrosine or absent,

X 5 is tyrosine or alanine or absent,

X 6 is cysteine or absent,

AA is any amino acid and n and p are integers between 0 and 2,

R 1 is the primary amine function of the N-terminal amino acid, free or substituted by a group of the acyl type (R—CO—) wherein the radical R is either a saturated or unsaturated C 1 to C 30 alkyl chain of the acetyl type, or an aromatic group of the benzoyl, tosyl, or benzyloxycarbonyl type,

R 2 is the hydroxyl group of the carboxyl function of the C-terminal amino acid, substituted by a group chosen from a C 1 to C 30 alkyl chain, or an NH 2 , NHY or NYY group with Y representing a C 1 to C 4 alkyl chain or one of the salts thereof,

R 3 is the thiol function of cysteine in the X 6 position, wherein the thiol function is free or substituted by a methyl group or an acetyl group, or the thiol function is covalently bound by a disulfide bond to another cysteine; and

a physiologically acceptable medium,

wherein said peptide of formula (I) is a dermatopontin-activating agent; and

with the proviso that when X 1 is absent, n is 0.

5. The composition of claim 4 , wherein said peptide is present in a concentration of between 10 −9 M and 10 −3 M with respect to the total weight of the composition.

6. The composition of claim 4 wherein the composition is suitable for topical administration.

7. The composition of claim 4 further comprising at least one other active agent.

8. The composition of claim 4 , wherein said peptide is present in a concentration of between 10 −8 M and 10 −5 M with respect to the total weight of the composition.

9. The composition of claim 4 , wherein said peptide of general formula (I) is

(SEQ ID NO: 1)

Asp-Arg-Gln-Trp-NH 2 ,

(SEQ ID NO: 2)

Asp-Arg-Glu-Trp-NH 2 ,

(SEQ ID NO: 3)

Asp-Arg-Gln-Trp-Asn-Tyr-NH 2 ,

(SEQ ID NO: 4)

Arg-Glu-Trp-Gln-Phe-Tyr-Cys-NH 2 ,

(SEQ ID NO: 5)

Arg-Glu-Trp-Gln-Phe-Tyr-Cys(Cys)-(NH 2 ),

(SEQ ID NO: 6)

Asp-Arg-Glu-Trp-Gln-Phe-NH 2 ,

(SEQ ID NO: 7)

Asp-Arg-Gln-Trp-Asn-Tyr-Ala-Cys-NH 2 ,

(SEQ ID NO: 8)

Asp-Arg-Gln-Trp-Asn-Tyr-Ala-Cys(Cys)-(NH 2 ),

(SEQ ID NO: 9)

Asp-Arg-Glu-Trp-Gln-Phe-Tyr-Cys-NH 2 ,

(SEQ ID NO: 10)

Asp-Arg-Glu-Trp-Gln-Phe-Tyr-Cys(Cys)-(NH 2 ),

(SEQ ID NO: 11)

Asp-Arg-Gln-Trp-Lys-Phe-NH 2 ,

(SEQ ID NO: 12)

Arg-Glu-Trp-Gln-Phe-Tyr-NH 2 .

10. The composition of claim 4 , wherein said peptide of general formula (I) is solubilized in one or more physiologically acceptable solvents selected from the group consisting of water, glycerol, ethanol, propanediol, butylene glycol, dipropylene glycol, the ethoxylated or propoxylated diglycols, the cyclic polyols, and mixtures of these solvents.

11. A method of treating the cutaneous signs of aging and photoaging, the method comprising:

providing a composition comprising a peptide of general formula (I):

R 1 -(AA) n -X 1 -Arg-X 2 -Trp-X 3 -X 4 -X 5 -X 6 (R 3 )-(AA) p -R 2

wherein,

X 1 is aspartic acid or absent,

X 2 is glutamine or glutamic acid,

X 3 is asparagine or lysine or glutamine or absent,

X 4 is phenylalanine or tyrosine or absent,

X 5 is tyrosine or alanine or absent,

X 6 is cysteine or absent,

AA is any amino acid and n and p are integers between 0 and 2,

R 1 is the primary amine function of the N-terminal amino acid, free or substituted by a group of the acyl type (R—CO—) wherein the radical R is either a saturated or unsaturated C 1 to C 30 alkyl chain of the acetyl type, or an aromatic group of the benzoyl, tosyl, or benzyloxycarbonyl type,

R 2 is the hydroxyl group of the carboxyl function of the C-terminal amino acid, substituted by a group chosen from a C 1 to C 30 alkyl chain, or an NH 2 , NHY or NYY group with Y representing a C 1 to C 4 alkyl chain or one of the salts thereof,

R 3 is the thiol function of cysteine in the X 6 position, wherein the thiol function is free or substituted by a methyl group or an acetyl group, or the thiol function is covalently bound by a disulfide bond to another cysteine; and

applying the composition to the skin before or after exposure to the sun;

with the proviso that when X 1 is absent, n is 0.

12. The method of claim 11 , wherein the peptide is an active agent that increases the expression of proteins of the extracellular matrix by the fibroblasts of the skin or increases regeneration of the epidermis and dermis.

13. The method of claim 11 , wherein applying occurs after exposure to sun, and the composition reduces degradation of collagen and elastic fibers in the skin.

14. The method of claim 11 , wherein said peptide is present in a concentration of between 10 −9 M and 10 −3 M with respect to the total weight of the composition.

15. The method of claim 11 , wherein said peptide of general formula (I) is

(SEQ ID NO: 1)

Asp-Arg-Gln-Trp-NH 2 ,

(SEQ ID NO: 2)

Asp-Arg-Glu-Trp-NH 2 ,

(SEQ ID NO: 3)

Asp-Arg-Gln-Trp-Asn-Tyr-NH 2 ,

(SEQ ID NO: 4)

Arg-Glu-Trp-Gln-Phe-Tyr-Cys-NH 2 ,

(SEQ ID NO: 5)

Arg-Glu-Trp-Gln-Phe-Tyr-Cys(Cys)-(NH 2 ),

(SEQ ID NO: 6)

Asp-Arg-Glu-Trp-Gln-Phe-NH 2 ,

(SEQ ID NO: 7)

Asp-Arg-Gln-Trp-Asn-Tyr-Ala-Cys-NH 2 ,

(SEQ ID NO: 8)

Asp-Arg-Gln-Trp-Asn-Tyr-Ala-Cys(Cys)-(NH 2 ),

(SEQ ID NO: 9)

Asp-Arg-Glu-Trp-Gln-Phe-Tyr-Cys-NH 2 ,

(SEQ ID NO: 10)

Asp-Arg-Glu-Trp-Gln-Phe-Tyr-Cys(Cys)-(NH 2 ),

(SEQ ID NO: 11)

Asp-Arg-Gln-Trp-Lys-Phe-NH 2 ,

(SEQ ID NO: 12)

Arg-Glu-Trp-Gln-Phe-Tyr-NH 2 .

16. The method of claim 11 , wherein said peptide of general formula (I) is solubilized in one or more physiologically acceptable solvents selected from the group consisting of water, glycerol, ethanol, propanediol, butylene glycol, dipropylene glycol, the ethoxylated or propoxylated diglycols, the cyclic polyols, and mixtures of these solvents.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 10, 2020
From: THE BANK OF NOVA SCOTIA
To: AVOCA LLC; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES LLC
Reel/Frame 051557/0504 →
SECURITY AGREEMENT Recorded Jul 3, 2017
From: AVOCA, INC.; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES, INC.
To: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT
Reel/Frame 043084/0753 →
CONVERSION Recorded Jan 30, 2017
From: ISP INVESTMENTS INC.
To: ISP INVESTMENTS LLC
Reel/Frame 041556/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2013
From: DAL FARRA, CLAUDE; DOMLOGE, NOUHA; BOTTO, JEAN-MARIE
To: ISP INVESTMENTS INC.
Reel/Frame 031243/0269 →